Financial Survey: Atossa Therapeutics (NASDAQ:ATOS) vs. NLS Pharmaceutics (NASDAQ:NLSP)

Atossa Therapeutics (NASDAQ:ATOS) and NLS Pharmaceutics (NASDAQ:NLSP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Volatility and Risk

Atossa Therapeutics has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, NLS Pharmaceutics has a beta of -0.39, meaning that its share price is 139% less volatile than the S&P 500.

Institutional & Insider Ownership

12.7% of Atossa Therapeutics shares are owned by institutional investors. 7.6% of Atossa Therapeutics shares are owned by company insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Atossa Therapeutics and NLS Pharmaceutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Therapeutics	0	0	3	0	3.00
NLS Pharmaceutics	0	0	0	0	0.00

Atossa Therapeutics currently has a consensus price target of $7.00, indicating a potential upside of 674.59%. Given Atossa Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Atossa Therapeutics is more favorable than NLS Pharmaceutics.

Profitability

This table compares Atossa Therapeutics and NLS Pharmaceutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atossa Therapeutics	N/A	-35.74%	-33.51%
NLS Pharmaceutics	N/A	N/A	N/A

Earnings & Valuation

This table compares Atossa Therapeutics and NLS Pharmaceutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Therapeutics	N/A	N/A	-$30.09 million	($0.22)	-4.11
NLS Pharmaceutics	N/A	N/A	-$12.17 million	N/A	N/A

Summary

Atossa Therapeutics beats NLS Pharmaceutics on 5 of the 9 factors compared between the two stocks.

About Atossa Therapeutics

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

About NLS Pharmaceutics

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.